MCID: SKN022
MIFTS: 53

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Skin 12 72
Squamous Cell Carcinoma of the Skin 6
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 50 C4819
UMLS 72 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to keratinizing squamous cell carcinoma and adenocarcinoma. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Human cytomegalovirus infection and Endometrial cancer. The drugs Fluorouracil and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 keratinizing squamous cell carcinoma 30.8 TP53 CDKN2A
2 adenocarcinoma 30.2 TP53 HRAS CDKN2A BRAF
3 glioblastoma 29.9 TP53 RAC1 HRAS CDKN2A BRAF
4 leukemia, chronic lymphocytic 29.7 TP53 MIR154 HRAS BRAF B2M
5 meningioma, familial 29.6 TP53 KLF4 CDKN2A
6 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.8
7 pseudovascular skin squamous cell carcinoma 12.4
8 acantholytic squamous cell skin carcinoma 11.9
9 clear cell squamous cell skin carcinoma 11.6
10 epidermodysplasia verruciformis 1 11.6
11 anal margin squamous cell carcinoma 11.4
12 squamous cell carcinoma 10.9
13 melanomatosis 10.8 HRAS CDKN2A
14 serous cystadenocarcinoma 10.7 TP53 HRAS FBXW7
15 nasal cavity adenocarcinoma 10.7 TP53 HRAS CDKN2A
16 cystadenocarcinoma 10.7 TP53 HRAS FBXW7
17 prostate adenoid cystic carcinoma 10.7 LRRC56 HRAS
18 anal squamous cell carcinoma 10.6 TP53 FBXW7 CDKN2A
19 epithelial-myoepithelial carcinoma 10.6 TP53 HRAS FBXW7
20 cell type benign neoplasm 10.6 TP53 HRAS CDKN2A
21 respiratory system cancer 10.6 TP53 HRAS CDKN2A
22 meningeal melanomatosis 10.5 TP53 HRAS CDKN2A B2M
23 prostate squamous cell carcinoma 10.5 TP53 LRRC56 HRAS B2M
24 skin carcinoma 10.5
25 uterine carcinosarcoma 10.5 TP53 LRRC56 HRAS FBXW7
26 gastrointestinal system cancer 10.5 TP53 HRAS CDKN2A
27 nevus of ota 10.4 TP53 BRAF
28 noonan syndrome 3 10.4 LRRC56 IFNA1 HRAS
29 acquired immunodeficiency syndrome 10.4 TP53 IFNA1 B2M
30 endocrine gland cancer 10.4 TP53 HRAS CDKN2A
31 gastrointestinal system disease 10.4 TP53 IFNA1 HRAS CDKN2A
32 gallbladder adenoma 10.4 HRAS CDKN2A
33 bladder squamous cell carcinoma 10.3 TP53 CDKN2A BRAF
34 in situ carcinoma 10.3
35 histiocytic sarcoma 10.3 CDKN2A BRAF
36 basal cell carcinoma 10.3
37 pulmonic stenosis 10.3 LRRC56 HRAS BRAF
38 skin melanoma 10.3 TP53 CDKN2A BRAF
39 leukemia, chronic lymphocytic 2 10.3 TP53 HRAS BRAF
40 inverted follicular keratosis 10.3
41 colorectal adenocarcinoma 10.3 TP53 HRAS BRAF
42 hyperplastic polyposis syndrome 10.2 TP53 BRAF
43 testicular germ cell tumor 10.2 TP53 HRAS BRAF
44 differentiated thyroid carcinoma 10.2 TP53 HRAS BRAF
45 keratosis, seborrheic 10.2
46 exanthem 10.2
47 adenoid squamous cell carcinoma 10.2
48 transitional cell carcinoma 10.2 TP53 HRAS CDKN2A BRAF
49 renal cell carcinoma, papillary, 1 10.2 TP53 HRAS BRAF
50 melanoma, cutaneous malignant 1 10.2 TP53 HRAS CDKN2A BRAF

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.02 B2M BRAF CDKN2A FBXW7 HRAS IGF2BP1
2 endocrine/exocrine gland MP:0005379 9.97 B2M BRAF CDKN2A FBXW7 HRAS IGF2BP1
3 hematopoietic system MP:0005397 9.96 B2M BRAF CD151 CDKN2A FBXW7 IGF2BP1
4 craniofacial MP:0005382 9.95 BRAF FBXW7 HRAS IGF2BP1 KLF4 RAC1
5 integument MP:0010771 9.81 B2M BRAF CD151 CDKN2A FBXW7 HRAS
6 liver/biliary system MP:0005370 9.5 B2M BRAF CDKN2A FBXW7 IGF2BP1 TNFAIP8L2
7 neoplasm MP:0002006 9.28 B2M BRAF CD151 CDKN2A FBXW7 HRAS

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4 51-21-8 3385
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3 Immunosuppressive Agents Phase 4
4 Antimetabolites Phase 4
5 Antimetabolites, Antineoplastic Phase 4
6 Immunologic Factors Phase 4
7 triamcinolone acetonide Phase 4
8 Triamcinolone hexacetonide Phase 4
9 Tin Fluorides Phase 4
10 Triamcinolone diacetate Phase 4
11
Mycophenolic acid Approved Phase 3 24280-93-1 446541
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
14
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
15 Anti-Infective Agents Phase 3
16 Antiparasitic Agents Phase 3
17 Antiprotozoal Agents Phase 3
18 Antirheumatic Agents Phase 3
19 Antifungal Agents Phase 3
20 Cyclosporins Phase 3
21 Calcineurin Inhibitors Phase 3
22
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
25
Gemcitabine Approved Phase 2 95058-81-4 60750
26
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
27
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
28
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
29
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
30
Pembrolizumab Approved Phase 2 1374853-91-4
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
32
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
33
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
34
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
35
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
36
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
37
Lenalidomide Approved Phase 2 191732-72-6 216326
38
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
39
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
40
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
41
Levulinic acid Experimental Phase 2 123-76-2 11579
42 Sunscreening Agents Phase 1, Phase 2
43 Semaxinib Phase 2
44 Cola Phase 2
45 Antineoplastic Agents, Phytogenic Phase 2
46 Albumin-Bound Paclitaxel Phase 2
47 Tubulin Modulators Phase 2
48 Antimitotic Agents Phase 2
49 Antibodies Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
2 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
3 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
4 A Multicentric, Randomized, Opened Study to Evaluate Efficacy on Renal Function of an Immunosuppressant Regimen Based on Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil, From the Second Year of Renal Transplantation Completed NCT00213590 Phase 3 cyclosporine A
5 Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance Terminated NCT02655068 Phase 3
6 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
7 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
8 Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT01198028 Phase 2 Erlotinib
9 A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses Completed NCT00002975 Phase 2 aminolevulinic acid
10 Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
11 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
12 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib
13 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
14 Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR. Completed NCT00240682 Phase 2 cetuximab
15 A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
16 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
17 Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) Completed NCT00625573 Phase 2 Abraxane
18 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
19 Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion Completed NCT03127670 Phase 2 Solanum melongena peel extract 0.05%
20 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
21 Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC) Completed NCT00464295 Phase 2 Capecitabine in HCC
22 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed NCT00212043 Phase 2 carboplatin and gemcitabine
23 Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) Recruiting NCT03944941 Phase 2 Avelumab;Cetuximab
24 A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma Recruiting NCT02964559 Phase 2
25 UNresectable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy. A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab With Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma Recruiting NCT03737721 Phase 2
26 A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
27 Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Active, not recruiting NCT02883556 Phase 2 Pembrolizumab
28 CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG) Active, not recruiting NCT02056756 Phase 1, Phase 2 Carfilzomib
29 Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients Enrolling by invitation NCT02347813 Phase 2 Pioglitazone
30 A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Terminated NCT01823679 Phase 2 Capecitabine
31 Phase I-II Study of ZD1839 (IRESSA®), Cisplatin, and External-Beam Radiation Therapy in Patients With Locally Advanced, Non-Metastatic, Squamous Cell Carcinoma of the Head and Neck Terminated NCT00195078 Phase 1, Phase 2 ZD1839 (IRESSA);Cisplatin
32 A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology Terminated NCT00005097 Phase 2 Polyphenon E and Placebo
33 A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes Terminated NCT01379274 Phase 2 Lenalidomide and azacitidine combination
34 Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin Terminated NCT01059305 Phase 2 Erlotinib
35 Development of an Electrical Diagnostic for Melanoma and Other Cutaneous Malignancies Unknown status NCT00391300 Phase 1
36 A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions Completed NCT02428036 Phase 1
37 Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Completed NCT01017185 Phase 1 HF10
38 Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions Completed NCT00103246 Phase 1 silicon phthalocyanine 4
39 Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma Recruiting NCT03291002 Phase 1
40 Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers Completed NCT00003611 acitretin
41 Chemoprevention Trial of Acitretin Versus Placebo in Patients at High Risk for Basal Cell Carcinoma or Squamous Cell Carcinoma Completed NCT00644384 acitretin
42 Transcriptional Profiling of the Epidermal Response to Solar-Simulated Ultraviolet Radiation Completed NCT00099112
43 Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer Completed NCT00900302
44 Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients Completed NCT02095912
45 Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H&E Histology Completed NCT01540695
46 Association of Viral Reactivation and Skin Cancer in Organ Transplant Recipients Completed NCT02395562
47 Prospektive Therapie-Studie Zur Behandlung Des Desmoplastischen Plattenepithelkarzinoms Recruiting NCT02717936
48 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma Recruiting NCT03353077
49 A Multicenter Pilot Study of Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma Recruiting NCT02131805
50 Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs] Recruiting NCT02310503

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

41
Skin, Lymph Node, Colon, Salivary Gland, Kidney, Lung, Breast

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 283)
# Title Authors PMID Year
1
Effect of Doxorubicin on Squamous Cell Carcinoma of Skin: Assessment by MRI Relaxometry at 4.7T. 38
31412717 2019
2
A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases. 38
31004003 2019
3
Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma. 38
31177167 2019
4
Squamous cell carcinoma of skin due to prolonged indwelling percutaneous nephrostomy catheter. 38
31129641 2019
5
Cancer Risk in Klippel-Trenaunay Syndrome. 38
31045469 2019
6
Investigation on the Cancer Invasion and Metastasis of Skin Squamous Cell Carcinoma by Raman Spectroscopy. 38
31151168 2019
7
Loss of Rab25 promotes the development of skin squamous cell carcinoma through the dysregulation of integrin trafficking. 38
31144312 2019
8
Silencing of EPHB2 promotes the epithelial-mesenchymal transition of skin squamous cell carcinoma-derived A431 cells. 38
30881495 2019
9
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. 38
31112973 2019
10
Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma. 38
30383661 2018
11
Associations Between IL-10 Polymorphisms and Susceptibility to Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma: A Meta-Analysis. 38
30427744 2018
12
Tamoxifen inhibits the proliferation of non‑melanoma skin cancer cells by increasing intracellular calcium concentration. 38
30226592 2018
13
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression. 38
30559930 2018
14
Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers. 38
29933892 2018
15
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. 38
29663367 2018
16
Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. 38
29727714 2018
17
IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. 38
29753746 2018
18
Superficial resection combined with photodynamic therapy for successful treatment of facial lupus vulgaris with squamous cell carcinoma. 38
29476827 2018
19
Novel RSPO1 mutation causing 46,XX testicular disorder of sex development with palmoplantar keratoderma: A review of literature and expansion of clinical phenotype. 38
29575617 2018
20
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. 38
29428730 2018
21
Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. 38
30025490 2018
22
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. 38
29050985 2018
23
Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. 38
29843147 2018
24
125I seeds implantation for an elderly patient of skin squamous cell carcinomas with ulcer guided by ultrasound. 38
30589056 2018
25
CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development. 38
28904130 2017
26
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. 38
28945253 2017
27
Squamous Cell Carcinoma of Skin after 20 Years of Renal Transplantation. 38
29217883 2017
28
Leiomyosarcoma of the infratemporal fossa with perineurial spread along the right mandibular nerve: a case report. 38
28990793 2017
29
Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients. 38
28207636 2017
30
Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth. 38
28807942 2017
31
Automatic discrimination of actinic keratoses from clinical photographs. 38
28692931 2017
32
Characterisation of the cancer-associated glucocorticoid system: key role of 11β-hydroxysteroid dehydrogenase type 2. 38
28797028 2017
33
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. 38
28623128 2017
34
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. 38
28672959 2017
35
Effects of demethoxycurcumin on the viability and apoptosis of skin cancer cells. 38
28586041 2017
36
TCF7L1 promotes skin tumorigenesis independently of β-catenin through induction of LCN2. 38
28467300 2017
37
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. 38
27714753 2017
38
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. 38
28176443 2017
39
[Pathologic changes of spontaneous tumors in Sprague-Dawley and Wistar rats]. 38
28376591 2017
40
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. 38
28593886 2017
41
An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin. 38
27601059 2017
42
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. 38
28607908 2017
43
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. 38
28507641 2017
44
Inguinal lymph node presenting as the delayed site of metastasis in early stage endometrial carcinoma: Case report. 38
28213066 2017
45
Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts. 38
28267785 2017
46
Association Between β-Genus Human Papillomavirus and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals-A Meta-analysis. 38
26720285 2016
47
Photothermal therapeutic effect of PEGylated gold nano-semicubes in chemically-induced skin cancer in mice. 38
27636008 2016
48
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. 38
27193637 2016
49
[Occurrence of associated tumours in chronic lymphocytic leukemia]. 38
27796128 2016
50
Successful treatment of cutaneous squamous cell carcinoma with intralesional cryosurgery: Case report. 38
27684856 2016

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

6 (show top 50) (show all 107)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
4 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
5 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
6 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
7 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
8 BRAF NM_004333.6(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 7:140481403-140481403 7:140781603-140781603
9 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
10 BRAF NM_004333.6(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
11 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
12 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
13 BRAF NM_004333.6(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
14 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
15 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
16 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
17 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
18 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
19 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
20 HRAS NM_005343.4(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 11:534285-534285 11:534285-534285
21 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
22 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
23 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
24 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 17:7577538-7577538 17:7674220-7674220
25 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
26 TP53 NM_000546.5(TP53): c.809T> C (p.Phe270Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519986 17:7577129-7577129 17:7673811-7673811
27 HRAS NM_005343.4(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 11:534286-534286 11:534286-534286
28 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Pathogenic/Likely pathogenic rs730882008 17:7577093-7577093 17:7673775-7673775
29 TP53 NM_000546.5(TP53): c.722C> A (p.Ser241Tyr) single nucleotide variant Likely pathogenic rs28934573 17:7577559-7577559 17:7674241-7674241
30 TP53 NM_000546.5(TP53): c.721T> C (p.Ser241Pro) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
31 TP53 NM_000546.5(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 17:7577560-7577560 17:7674242-7674242
32 TP53 NM_000546.5(TP53): c.373A> C (p.Thr125Pro) single nucleotide variant Likely pathogenic rs1057520003 17:7579314-7579314 17:7675996-7675996
33 TP53 NM_000546.5(TP53): c.638G> T (p.Arg213Leu) single nucleotide variant Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
34 TP53 NM_000546.5(TP53): c.637C> G (p.Arg213Gly) single nucleotide variant Likely pathogenic rs397516436 17:7578212-7578212 17:7674894-7674894
35 TP53 NM_000546.5(TP53): c.742C> G (p.Arg248Gly) single nucleotide variant Likely pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
36 TP53 NM_000546.5(TP53): c.535C> G (p.His179Asp) single nucleotide variant Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
37 TP53 NM_000546.5(TP53): c.536A> C (p.His179Pro) single nucleotide variant Likely pathogenic rs1057519991 17:7578394-7578394 17:7675076-7675076
38 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 17:7577124-7577124 17:7673806-7673806
39 TP53 NM_000546.5(TP53): c.646G> T (p.Val216Leu) single nucleotide variant Likely pathogenic rs730882025 17:7578203-7578203 17:7674885-7674885
40 TP53 NM_000546.5(TP53): c.647T> G (p.Val216Gly) single nucleotide variant Likely pathogenic rs1057520004 17:7578202-7578202 17:7674884-7674884
41 TP53 NM_000546.5(TP53): c.647T> A (p.Val216Glu) single nucleotide variant Likely pathogenic rs1057520004 17:7578202-7578202 17:7674884-7674884
42 TP53 NM_000546.5(TP53): c.815T> A (p.Val272Glu) single nucleotide variant Likely pathogenic rs876660333 17:7577123-7577123 17:7673805-7673805
43 TP53 NM_000546.5(TP53): c.707A> G (p.Tyr236Cys) single nucleotide variant Likely pathogenic rs730882026 17:7577574-7577574 17:7674256-7674256
44 TP53 NM_000546.5(TP53): c.810T> G (p.Phe270Leu) single nucleotide variant Likely pathogenic rs1057519987 17:7577128-7577128 17:7673810-7673810
45 TP53 NM_000546.5(TP53): c.841G> C (p.Asp281His) single nucleotide variant Likely pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
46 TP53 NM_000546.5(TP53): c.842A> C (p.Asp281Ala) single nucleotide variant Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
47 TP53 NM_000546.5(TP53): c.856G> C (p.Glu286Gln) single nucleotide variant Likely pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
48 TP53 NM_000546.5(TP53): c.857A> T (p.Glu286Val) single nucleotide variant Likely pathogenic rs1057519985 17:7577081-7577081 17:7673763-7673763
49 TP53 NM_000546.5(TP53): c.857A> C (p.Glu286Ala) single nucleotide variant Likely pathogenic rs1057519985 17:7577081-7577081 17:7673763-7673763
50 TP53 NM_000546.5(TP53): c.808T> A (p.Phe270Ile) single nucleotide variant Likely pathogenic rs1057519988 17:7577130-7577130 17:7673812-7673812

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 6898)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 16:31061111-31061111 18
2 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 16:31062050-31062050 18
3 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 16:31064213-31064213 18
4 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 18
5 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 18
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 3:147396258-147396258 18
7 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 3:147396018-147396018 18
8 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 3:147391059-147391059 18
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 3:147395971-147395971 18
10 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 3:147396226-147396226 18
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13:99982979-99982979 18
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 2:43225235-43225235 18
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 2:43225208-43225208 18
14 COSM6963526 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1646C>T p.S549F 16:72958500-72958500 18
15 COSM6974401 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.2933C>T p.A978V 16:72950752-72950752 18
16 COSM6934239 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10688G>A p.R3563K 16:72787588-72787588 18
17 COSM6934240 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.727G>A p.D243N 16:72959419-72959419 18
18 COSM6926616 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10999G>A p.D3667N 16:72787277-72787277 18
19 COSM6944080 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1138C>T p.P380S 16:72959008-72959008 18
20 COSM6926265 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10577G>A p.G3526D 16:72787699-72787699 18
21 COSM6944931 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.7759C>T p.Q2587* 16:72794923-72794923 18
22 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 22:49883990-49883990 18
23 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 23:2490119-2490119 18
24 COSM228200 YES1 skin,NS,carcinoma,squamous cell carcinoma c.1499C>T p.S500F 18:724557-724557 18
25 COSM6932261 YES1 skin,NS,carcinoma,squamous cell carcinoma c.373G>A p.E125K 18:748017-748017 18
26 COSM6982918 YES1 skin,NS,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 18
27 COSM6932242 YAP1 skin,NS,carcinoma,squamous cell carcinoma c.938C>T p.S313F 11:102223689-102223689 18
28 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 2:61488193-61488193 18
29 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 3:14158444-14158444 18
30 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 3:14148727-14148727 18
31 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 3:14148728-14148728 18
32 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 3:14147977-14147977 18
33 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 3:14147976-14147976 18
34 COSM6884834 WT1 skin,NS,carcinoma,squamous cell carcinoma c.964C>T p.P322S 11:32396338-32396338 18
35 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 11:32417597-32417597 18
36 COSM6939000 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1046-1G>T p.? 11:32392756-32392756 18
37 COSM6917498 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1034G>A p.R345K 11:32396268-32396268 18
38 COSM28974 WT1 skin,NS,carcinoma,squamous cell carcinoma c.935G>A p.R312Q 11:32396367-32396367 18
39 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 14:67659823-67659823 18
40 COSM6909326 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.137G>A p.G46E 1:117156882-117156882 18
41 COSM6909324 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.610G>A p.E204K 1:117153205-117153205 18
42 COSM6972902 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.134C>T p.A45V 1:117156885-117156885 18
43 COSM6912242 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.628G>A p.V210I 1:117153187-117153187 18
44 COSM6967157 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.236T>A p.L79* 1:117156783-117156783 18
45 COSM14356 VHL skin,NS,carcinoma,squamous cell carcinoma c.394C>T p.Q132* 3:10146567-10146567 18
46 COSM30228 VHL skin,NS,carcinoma,squamous cell carcinoma c.337C>T p.R113* 3:10142184-10142184 18
47 COSM6937204 VEGFA skin,NS,carcinoma,squamous cell carcinoma c.701C>T p.P234L 6:43777511-43777511 18
48 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 3:124737589-124737589 18
49 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 3:124737588-124737588 18
50 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 3:124738100-124738100 18

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 TP53 RAC1 IFNA1 HRAS CDKN2A B2M
2
Show member pathways
12.68 TP53 RAC1 HRAS CDKN2A BRAF
3 12.57 TP53 RAC1 IFNA1 HRAS CDKN2A BRAF
4
Show member pathways
12.4 TP53 RAC1 HRAS BRAF
5 12.37 TP53 IGF2BP1 HRAS CDKN2A
6
Show member pathways
12.34 RAC1 IFNA1 HRAS BRAF
7
Show member pathways
12.32 TP53 RAC1 HRAS BRAF
8
Show member pathways
12.08 TP53 RAC1 HRAS BRAF
9 12.08 TP53 RAC1 HRAS CDKN2A
10 12.07 TP53 RAC1 HRAS BRAF
11
Show member pathways
11.89 TP53 RAC1 HRAS BRAF
12 11.68 TP53 RAC1 HRAS CDKN2A
13 11.58 TP53 HRAS CDKN2A BRAF
14 11.49 TP53 HRAS FBXW7
15 11.25 TP53 RAC1 HRAS
16 11.12 TP53 HRAS CDKN2A BRAF
17 11.07 TP53 RAC1 HRAS CDKN2A BRAF
18 10.67 TP53 RAC1 CDKN2A

GO Terms for Skin Squamous Cell Carcinoma

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.35 TP53 KLF4 HRAS CDKN2A BRAF
2 Ras protein signal transduction GO:0007265 9.33 TP53 HRAS CDKN2A
3 replicative senescence GO:0090399 9.26 TP53 CDKN2A
4 regulation of axon regeneration GO:0048679 8.62 KLF4 BRAF

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....